Catalog No.
DHK06601
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
IgG4-kappa
Clonality
Monoclonal
Target
LOXL2, Lysyl oxidase-related protein WS9-14, Lysyl oxidase homolog 2, Lysyl oxidase-like protein 2, Lysyl oxidase-related protein 2
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q9Y4K0
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
AB0024, GS-6624, CAS: 1318075-13-6
Clone ID
Simtuzumab
Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis, PMID: 29990488
Is This the Last Requiem for Simtuzumab?, PMID: 30303551
The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials, PMID: 30993748
Simtuzumab for Primary Sclerosing Cholangitis: Phase 2 Study Results With Insights on the Natural History of the Disease, PMID: 30153359
Lysyl Oxidase (LOX) Family Members: Rationale and Their Potential as Therapeutic Targets for Liver Fibrosis, PMID: 32176358
The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial, PMID: 28892558
Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease, PMID: 27646933
Risk factors for disease progression in idiopathic pulmonary fibrosis, PMID: 31611341
Great expectations for simtuzumab in IPF fall short, PMID: 27939077
A phase 2 study of simtuzumab in patients with primary, post-polycythaemia vera or post-essential thrombocythaemia myelofibrosis, PMID: 28220932
Simtuzumab treatment of advanced liver fibrosis in HIV and HCV-infected adults: results of a 6-month open-label safety trial, PMID: 27232579
The Association of Histologic and Noninvasive Tests With Adverse Clinical and Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis, PMID: 33307033
Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: a randomised, double-blind, controlled, phase 2 trial, PMID: 27939076
A Phase II Randomized, Double-Blind, Placebo-Controlled Study of Simtuzumab or Placebo in Combination with Gemcitabine for the First-Line Treatment of Pancreatic Adenocarcinoma, PMID: 28246206
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Simtuzumab in Combination with FOLFIRI for the Second-Line Treatment of Metastatic KRAS Mutant Colorectal Adenocarcinoma, PMID: 28246207
A quick overview to the early phase clinical trials of Simtuzumab®: Are we loosing the most promising anti-fibrotic product?, PMID: 29055391
Emerging Treatments for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis, PMID: 29128056
Novel Pharmacotherapy Options for NASH, PMID: 27003143
Non-alcoholic fatty liver disease in 2015, PMID: 26085906
Therapy of Primary Sclerosing Cholangitis--Today and Tomorrow, PMID: 26641242
Inter- and Intra-individual Variation, and Limited Prognostic Utility, of Serum Alkaline Phosphatase in a Trial of Patients With Primary Sclerosing Cholangitis, PMID: 32707342
Emerging Therapies for Nonalcoholic Fatty Liver Disease, PMID: 27063275
[Treatment Options in Non-alcoholic Fatty Liver Disease], PMID: 28637104
Improvement of hepatic fibrosis and patient-reported outcomes in non-alcoholic steatohepatitis treated with selonsertib, PMID: 29377462
The 20% Rule of NASH Progression: The Natural History of Advanced Fibrosis and Cirrhosis Caused by NASH, PMID: 31520407
Methylation signatures in peripheral blood are associated with marked age acceleration and disease progression in patients with primary sclerosing cholangitis, PMID: 32039401
Spontaneous Fluctuations in Liver Biochemistries in Patients with Compensated NASH Cirrhosis: Implications for Drug Hepatotoxicity Monitoring, PMID: 31907854
Pioglitazone and bariatric surgery are the most effective treatments for non-alcoholic steatohepatitis: A hierarchical network meta-analysis, PMID: 33368954
Magnetic Resonance Elastography Shear Wave Velocity Correlates with Liver Fibrosis and Hepatic Venous Pressure Gradient in Adults with Advanced Liver Disease, PMID: 28480218
Controlling alpha for mixed effects models for repeated measures, PMID: 29461924
Statistical design for a confirmatory trial with a continuous predictive biomarker: A case study, PMID: 28522422
The role of LOX and LOXL2 in scar formation after glaucoma surgery, PMID: 23821193
For research use only. Not for human or drug use.
